Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension-Reference-Cited by-同舟云学术

Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension

Published:2017-07-26 Issue:9 Volume:92 Page:909-914
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Reilly Christopher R.¹^ORCID,Babushok Daria V.¹²,Martin Karlyn³,Spivak Jerry L.⁴,Streiff Michael⁴,Bahirwani Ranjeeta⁵,Mondschein Jeffrey⁶,Stein Brady³,Moliterno Alison⁴,Hexner Elizabeth O.¹²

Affiliation:

1. Department of Medicine; Hospital of the University of Pennsylvania; Philadelphia Pennsylvania

2. Abramson Cancer Center and the Division of Hematology & Oncology; Philadelphia Pennsylvania

3. Division of Hematology and Oncology; Northwestern University; Chicago Illinois

4. Department of Medicine; Johns Hopkins Hospital; Baltimore Maryland

5. Liver Consultants of Texas, Baylor University Medical Center; Dallas Texas

6. Department of Interventional Radiology; Hospital of the University of Pennsylvania; Philadelphia Pennsylvania

Funder

American Society of Hematology

Publisher

Wiley

Subject

Hematology

Reference41 articles.

1. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria;Wadleigh;Int J Hematol.,2010

2. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders;Baxter;Lancet.,2005

3. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera;James;Nature.,2005

4. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis;Levine;Cancer Cell.,2005

5. A gain-of-function mutation of JAK2 in myeloproliferative disorders;Kralovics;N Engl J Med.,2005

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Portosystemic Shunt and Portal Vein Stent in Managing Portal Hypertension Due to Hematological Diseases;Cureus;2024-02-14

2. Decreased patency of transjugular intrahepatic portosystemic shunts performed for splanchnic vein thrombosis in patients with myeloproliferative neoplasms;Thrombosis Research;2024-02

3. Efficacy and Safety of Transjugular Intrahepatic Portosystemic Shunt Creation for Budd-Chiari Syndrome: A Systematic Review and Meta-Analysis;Journal of Vascular and Interventional Radiology;2022-11

4. Splenic artery embolization for treatment of portal hypertension due to essential thrombocythemia;Portal Hypertension & Cirrhosis;2022-09

5. Characteristics of myeloproliferative neoplasm-associated portal hypertension and endoscopic management of variceal bleeding;Therapeutic Advances in Chronic Disease;2022-01